Please try another search
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
Name | Age | Since | Title |
---|---|---|---|
Sachio Kishii | 45 | 2017 | Independent Outside Director |
Kinichiro Kominami | 57 | 2018 | Independent Outside Director |
Kenzo Iizuka | 61 | 2013 | Director |
Shohei Yamamoto | 44 | 2015 | External Auditor |
Masaya Kimura | 68 | 2014 | Auditor |
Kiyoshi Eshima | - | - | President & Representative Director |
Masaaki Maeda | - | 2020 | Full-Time Auditor |
Kenichi Kurotaki | - | 2020 | Director |
Akifumi Taniguchi | - | 2021 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review